IVERIC bio 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   4 Trials   222 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Izervay (avacincaptad pegol intravitreal solution) / Astellas
NCT04435366 / 2020-000676-38: A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Completed
3
448
Europe, Canada, US, RoW
Avacincaptad Pegol, Zimura (previous name), IZERVAY, Sham
IVERIC bio, Inc.
Geographic Atrophy, Macular Degeneration
07/22
08/23
GATHER2, NCT05536297 / 2022-002860-59: Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Completed
3
278
Europe, Canada, US, RoW
avacincaptad pegol, Zimura (previous name), ARC1905, Izervay
Astellas Pharma Global Development, Inc., IVERIC bio, Inc.
Geographic Atrophy, Age-Related Macular Degeneration
04/25
04/25
NCT06970665: A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Recruiting
3
20
Japan
avacincaptad pegol, ASP3021, IZERVAY
Astellas Pharma Inc
Geographic Atrophy, Age-Related Macular Degeneration
06/27
06/27
NCT06659445: Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Not yet recruiting
2
324
NA
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
ONL Therapeutics
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
11/27
11/27
NCT03364153 / 2017-004783-35: Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Completed
2
121
Europe, US, RoW
avacincaptad pegol, Zimura (previous name), ARC1905, Izervay, Sham
Astellas Pharma Global Development, Inc.
Stargardt's Macular Dystrophy
03/25
03/25
NCT06961370: A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Recruiting
1
132
US
RO7669330, Syfovre™, Pegcetacoplan injection, Izervay™, Avacincaptad pegol IVT solution
Hoffmann-La Roche
Geographic Atrophy, Age-related Macular Degeneration
01/27
01/27
NCT06779773: A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Recruiting
N/A
1000
US
Avacincaptad pegol (ACP), IZERVAY™
Astellas Pharma Global Development, Inc.
Geographic Atrophy, Macular Degeneration
01/30
01/30
Fovista (pegpleranib) / Roche, Astellas
2013-005549-35: To establish the safety and tolerability of intravitreous administration of altering regimens of Fovista? (Anti-PDGF-B pegylated aptamer) administered in combination with Anti-VEGF therapy (Lucentis®, Avastin® or Eylea®) in subjects with subfoveal neovascular age-related macular degeneration. Evaluar la seguridad y la tolerabilidad de la administración intravítrea de diferentes pautas de Fovista? (aptámero pegilado anti-PDGF-B) y el tratamiento anti-VEGF (Lucentis®, Avastin® o Eylea®) en pacientes con degeneración macular neovascular asociada a la edad.

Ongoing
2
25
Europe
Fovista, Lucentis, Eylea, Avastin, E10030, Solution for injection, Lucentis 10 mg/mL, Eylea, Avastin
Barcelona Macula Foundation Research for Vision, Barcelona Macula Foundation
Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Diseases [C] - Eye Diseases [C11]
 
 
tivozanib ocular form / Astellas
No trials found
IC-500 / Astellas
No trials found
IC-100 / Astellas
No trials found
IC-200 / Astellas
No trials found
minicep290 / Astellas
No trials found
miniABCA4 / Astellas
No trials found
miniUSH2A / Astellas
No trials found
Drug for Vitelliform Macular Dystrophy / Astellas
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Izervay (avacincaptad pegol intravitreal solution) / Astellas
NCT04435366 / 2020-000676-38: A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Completed
3
448
Europe, Canada, US, RoW
Avacincaptad Pegol, Zimura (previous name), IZERVAY, Sham
IVERIC bio, Inc.
Geographic Atrophy, Macular Degeneration
07/22
08/23
GATHER2, NCT05536297 / 2022-002860-59: Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Completed
3
278
Europe, Canada, US, RoW
avacincaptad pegol, Zimura (previous name), ARC1905, Izervay
Astellas Pharma Global Development, Inc., IVERIC bio, Inc.
Geographic Atrophy, Age-Related Macular Degeneration
04/25
04/25
NCT06970665: A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Recruiting
3
20
Japan
avacincaptad pegol, ASP3021, IZERVAY
Astellas Pharma Inc
Geographic Atrophy, Age-Related Macular Degeneration
06/27
06/27
NCT06659445: Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Not yet recruiting
2
324
NA
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
ONL Therapeutics
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
11/27
11/27
NCT03364153 / 2017-004783-35: Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Completed
2
121
Europe, US, RoW
avacincaptad pegol, Zimura (previous name), ARC1905, Izervay, Sham
Astellas Pharma Global Development, Inc.
Stargardt's Macular Dystrophy
03/25
03/25
NCT06961370: A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Recruiting
1
132
US
RO7669330, Syfovre™, Pegcetacoplan injection, Izervay™, Avacincaptad pegol IVT solution
Hoffmann-La Roche
Geographic Atrophy, Age-related Macular Degeneration
01/27
01/27
NCT06779773: A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Recruiting
N/A
1000
US
Avacincaptad pegol (ACP), IZERVAY™
Astellas Pharma Global Development, Inc.
Geographic Atrophy, Macular Degeneration
01/30
01/30
Fovista (pegpleranib) / Roche, Astellas
2013-005549-35: To establish the safety and tolerability of intravitreous administration of altering regimens of Fovista? (Anti-PDGF-B pegylated aptamer) administered in combination with Anti-VEGF therapy (Lucentis®, Avastin® or Eylea®) in subjects with subfoveal neovascular age-related macular degeneration. Evaluar la seguridad y la tolerabilidad de la administración intravítrea de diferentes pautas de Fovista? (aptámero pegilado anti-PDGF-B) y el tratamiento anti-VEGF (Lucentis®, Avastin® o Eylea®) en pacientes con degeneración macular neovascular asociada a la edad.

Ongoing
2
25
Europe
Fovista, Lucentis, Eylea, Avastin, E10030, Solution for injection, Lucentis 10 mg/mL, Eylea, Avastin
Barcelona Macula Foundation Research for Vision, Barcelona Macula Foundation
Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Neovascular age-related macular degeneration Degeneración macular neovascular asociada a la edad., Diseases [C] - Eye Diseases [C11]
 
 
tivozanib ocular form / Astellas
No trials found
IC-500 / Astellas
No trials found
IC-100 / Astellas
No trials found
IC-200 / Astellas
No trials found
minicep290 / Astellas
No trials found
miniABCA4 / Astellas
No trials found
miniUSH2A / Astellas
No trials found
Drug for Vitelliform Macular Dystrophy / Astellas
No trials found

Download Options